ACROBiosystems社 Vaccine development in the post-COVID era

Decades in the Making | Heralding the Next Vaccine Revolution

The Next Target for mRNA Vaccines: HIV?

Utilizing the same mRNA technology from their COVID vaccines, Moderna is now entering Phase 1 clinical trials for their mRNA-based HIV vaccine. Earlier in 2021, this vaccine was shown to trigger the production of neutralizing antibodies against HIV-like viruses in monkeys, focusing on surface-bound glycoproteins, gp41 and gp120. Further research around these surface glycoprotein subunits has been shown to induce the production of antibodies that can neutralize over 80% of the virus.

A New Era of Structure-based Vaccine Design?

The journey in developing an RSV vaccine is nearing the end with the FDA's approval of GSK’s AREXVY. From the 1960s, RSV vaccine research was put at a standstill until the identification of a different protein conformation, the pre-fusion form. Focusing on the pre-fusion RSV F protein, vaccine design was improved significantly. Of course, this brings bigger hope not only to combat RSV but also to other vaccines, highlighting the role of protein structure in vaccine design.

RSV antigens and antibodies

Product Spotlight


SARS-CoV-2 Mutant Antigens, Antibodies and Kits	MHC Custom Services	Explore ViruStop

Learn more about RSV structural conformation analytical methods by downloading our application note!

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。